Novo To Secure Licensing Or M&A Deal By Mid-2018
Who is on Scrip’s list of potential licensing partners and M&A targets for Novo Nordisk, now that the company has renewed its hunt for new products to add to its hematology portfolio?
You may also be interested in...
Novo, which is under pressure to diversify and signaled plans to cut jobs back in August, will lay off 400 people as it reallocates resources to more efficiently bring in novel products through both R&D and business development, continuing a deal-making spree that's already under way.
Sanofi's €3.9bn acquisition of Ablynx will allow the French big pharma to build up its rare blood disorder pipeline and bring in complementary programs in areas like respiratory infections.
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.